MCID: THY025
MIFTS: 52

Thymus Cancer

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymus Cancer

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer 12 40 14
Thymic Carcinoma 12 72 55 51 14 69
Malignant Thymoma 12 55
Thymus Neoplasms 41 69
Malignant Neoplasm of Thymus 69
Neoplasm of Thymus 12
Thymoma, Malignant 12
Thymoma, Familial 69
Thymic Neoplasm 12
Thymoma, Type C 69
Thymus Neoplasm 72
Thymic Tumor 12

Characteristics:

Orphanet epidemiological data:

55
thymic carcinoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: any age;

Classifications:



Summaries for Thymus Cancer

MedlinePlus : 40 The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary : Thymus Cancer, also known as thymic carcinoma, is related to thymoma and large cell carcinoma, and has symptoms including hyperhidrosis, weight loss and dyspnea. An important gene associated with Thymus Cancer is CD5 (CD5 Molecule), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Development EGFR signaling pathway. The drugs Cisplatin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include thymus, testes and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A thymus cancer that derives from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.

Wikipedia : 72 Thymic carcinoma is a rare type of thymus gland cancer. It usually spreads, has a high risk of... more...

Related Diseases for Thymus Cancer

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 thymoma 31.0 CD5 DNTT DPYSL5 KIT NKX2-1
2 large cell carcinoma 29.6 EGFR KRT5 KRT7 NKX2-1 SYP
3 lymphoepithelioma-like thymic carcinoma 12.1
4 thymus adenocarcinoma 11.3
5 epithelial malignant thymoma 11.3
6 thymus squamous cell carcinoma 11.2
7 immunodeficiency with thymoma 11.1
8 thymus adenosquamous carcinoma 11.0
9 invasive malignant thymoma 10.9
10 noninvasive malignant thymoma 10.9
11 thymic epithelial tumor 10.6 CD5 KIT
12 lung acinar adenocarcinoma 10.6 KRT7 NKX2-1
13 mixed type thymoma 10.6 CD5 KIT SYP
14 reticular perineurioma 10.6 KIT MUC1
15 thymoma, familial 10.5
16 ovarian large-cell neuroendocrine carcinoma 10.5 KRT7 SYP
17 cutaneous ganglioneuroma 10.5 KIT SYP
18 sinonasal undifferentiated carcinoma 10.5 MUC1 SYP
19 small cell carcinoma of the bladder 10.5 KRT7 NKX2-1 SYP
20 jejunal cancer 10.5 KIT KRT7
21 inverted transitional papilloma 10.5 KRT5 KRT7
22 pulmonary sclerosing hemangioma 10.5 KRT7 NKX2-1 SYP
23 endometrial small cell carcinoma 10.5 KIT SMUG1 SYP
24 immune system organ benign neoplasm 10.5 CD5 KRT7 SYP
25 thymus lipoma 10.5 CD5 KRT7 SYP
26 balloon cell malignant melanoma 10.5 KRT5 KRT7
27 mucinous adenofibroma 10.5 KRT7 SYP
28 bartholin's duct cyst 10.5 SMUG1 TP53
29 perivascular epithelioid cell tumor 10.5 KIT MUC1 SYP
30 schneiderian carcinoma 10.5 KRT5 SMUG1
31 ovarian germ cell teratoma 10.5 KRT7 NKX2-1
32 malignant mixed mullerian tumor 10.5 KIT KRT7 MUC1
33 breast lymphoma 10.5 CD5 SMUG1
34 extraskeletal ewing sarcoma 10.5 MUC1 NKX2-1 SYP
35 spindle cell thymoma 10.5 CD5 MUC1
36 small cell neuroendocrine carcinoma 10.5 KIT SYP TP53
37 uterine body mixed cancer 10.5 KIT PIK3R2 TP53
38 dermoid cyst 10.5 KIT KRT7 MUC1
39 papillary serous adenocarcinoma 10.5 KRT7 NKX2-1 TP53
40 blastoma 10.5 NKX2-1 SYP TP53
41 cellular ependymoma 10.5 SMUG1 SYP TP53
42 gallbladder small cell carcinoma 10.4 SMUG1 SYP
43 papillary adenoma 10.4 KRT5 KRT7 NKX2-1
44 glycogen-rich clear cell breast carcinoma 10.4 KRT7 SYP TP53
45 sensory organ benign neoplasm 10.4 KRT5 KRT7 SYP
46 duodenum cancer 10.4 KRT7 MUC1 SYP
47 gastric tubular adenocarcinoma 10.4 KRT7 MUC1 SYP
48 papillary thymic adenocarcinoma 10.4 CALB2 CD5
49 chordoid glioma 10.4 MUC1 NKX2-1 TP53
50 granulosa cell tumor of the ovary 10.4 KRT7 SYP TP53

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer

Symptoms & Phenotypes for Thymus Cancer

Human phenotypes related to Thymus Cancer:

55 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000975
2 weight loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0001824
3 dyspnea 55 31 frequent (33%) Frequent (79-30%) HP:0002094
4 fatigable weakness 55 31 occasional (7.5%) Occasional (29-5%) HP:0003473
5 diaphragmatic paralysis 55 31 frequent (33%) Frequent (79-30%) HP:0006597
6 fatigue 55 31 occasional (7.5%) Occasional (29-5%) HP:0012378
7 cough 55 31 frequent (33%) Frequent (79-30%) HP:0012735
8 neoplasm of the thymus 55 31 hallmark (90%) Very frequent (99-80%) HP:0100521
9 palpebral edema 55 31 frequent (33%) Frequent (79-30%) HP:0100540
10 mediastinal lymphadenopathy 55 31 frequent (33%) Very frequent (99-80%) HP:0100721
11 chest pain 55 31 frequent (33%) Frequent (79-30%) HP:0100749
12 edema 55 Frequent (79-30%)
13 abnormality of the vena cava 55 Frequent (79-30%)
14 ptosis 31 occasional (7.5%) HP:0000508
15 cardiac arrest 31 occasional (7.5%) HP:0001695
16 pericarditis 31 occasional (7.5%) HP:0001701
17 abnormal bleeding 31 occasional (7.5%) HP:0001892
18 dysphagia 31 occasional (7.5%) HP:0002015
19 headache 31 occasional (7.5%) HP:0002315
20 language impairment 31 occasional (7.5%) HP:0002463
21 increased intracranial pressure 31 occasional (7.5%) HP:0002516
22 immunodeficiency 31 frequent (33%) HP:0002721
23 autoimmunity 31 occasional (7.5%) HP:0002960
24 dysgammaglobulinemia 31 frequent (33%) HP:0002961
25 neuroendocrine neoplasm 31 occasional (7.5%) HP:0100634
26 abnormal vena cava morphology 31 frequent (33%) HP:0005345

GenomeRNAi Phenotypes related to Thymus Cancer according to GeneCards Suite gene sharing:

25 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.83 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.83 POMC DNTT KIT PIK3R2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.83 PIK3R2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.83 PIK3R2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.83 DNTT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.83 POMC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.83 DNTT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.83 DNTT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.83 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.83 DNTT KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.83 DNTT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.83 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.83 DNTT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.83 DNTT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.83 PIK3R2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.83 POMC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.83 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.83 POMC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.83 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.83 PIK3R2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 DNTT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.83 PIK3R2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 KIT PIK3R2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.83 POMC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.83 POMC KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.83 KIT

MGI Mouse Phenotypes related to Thymus Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 AMPH CALB2 CD5 CNTNAP2 DPYSL5 EGFR
2 neoplasm MP:0002006 9.7 TP53 EGFR KIT NKX2-1 PIK3R2 POMC
3 no phenotypic analysis MP:0003012 9.23 CD5 EGFR KIT KRT5 NKX2-1 POMC

Drugs & Therapeutics for Thymus Cancer

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Bevacizumab Approved, Investigational Phase 2 216974-75-3
3
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
4
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
5
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
6
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
7
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
8 Amrubicin Approved, Investigational Phase 2 110267-81-7
9
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286 11431660 5005498
10
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
12
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
13
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
14
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
15
Saracatinib Investigational Phase 2 379231-04-6
16
Doxil Approved June 1999 Phase 1, Phase 2 31703
17 Antimitotic Agents Phase 2
18 Angiogenesis Inhibitors Phase 2
19 Angiogenesis Modulating Agents Phase 2
20
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
21 Protein Kinase Inhibitors Phase 2
22 insulin Phase 2
23 Insulin, Globin Zinc Phase 2
24 Mitogens Phase 2
25 Folic Acid Antagonists Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
27 Vitamin B Complex Phase 2,Phase 1
28 Histone Deacetylase Inhibitors Phase 2,Phase 1
29 Alkylating Agents Phase 1, Phase 2
30 Antirheumatic Agents Phase 1, Phase 2
31 Immunosuppressive Agents Phase 1, Phase 2
32 Anti-Bacterial Agents Phase 1, Phase 2
33 Antibiotics, Antitubercular Phase 1, Phase 2
34 Topoisomerase Inhibitors Phase 1, Phase 2
35 Folate Nutraceutical Phase 2,Phase 1
36 Vitamin B9 Nutraceutical Phase 2,Phase 1
37
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
38 Analgesics Phase 1
39 Analgesics, Non-Narcotic Phase 1
40 Anti-Inflammatory Agents Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 1
42 Cyclooxygenase 2 Inhibitors Phase 1
43 Cyclooxygenase Inhibitors Phase 1
44 Peripheral Nervous System Agents Phase 1
45 Vaccines Phase 1

Interventional clinical trials:

(show all 23)

# Name Status NCT ID Phase Drugs
1 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
2 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
3 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
4 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
5 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
6 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
7 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
8 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
9 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
10 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
11 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor Not yet recruiting NCT03219554 Phase 2 Palbociclib
12 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
13 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
14 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
15 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
16 Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting NCT03023319 Phase 1 Bosutinib;Pemetrexed
17 Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Active, not recruiting NCT01165658 Phase 1
18 Genetic Evaluation of Families With Endocrine Cancers Completed NCT01794676
19 Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors Completed NCT02233842
20 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
21 Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors Recruiting NCT02146170
22 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
23 Molecular Analysis of Thoracic Malignancies Enrolling by invitation NCT01385722

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Genetic Tests for Thymus Cancer

Anatomical Context for Thymus Cancer

MalaCards organs/tissues related to Thymus Cancer:

38
Thymus, Testes, Lung

Publications for Thymus Cancer

Articles related to Thymus Cancer:

# Title Authors Year
1
Sunitinib effective for rare thymus cancer. ( 25680712 )
2015
2
Gene mutation may signal indolent thymus cancer. ( 25185203 )
2014
3
Thymus cancer epidemiology in England and Wales. ( 2372494 )
1990

Variations for Thymus Cancer

Cosmic variations for Thymus Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44380 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 14
2 COSM14140 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 14
3 COSM6191487 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 14
4 COSM6191489 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 14
5 COSM2006821 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.11824C>T p.R3942W 14
6 COSM133763 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 14
7 COSM6191682 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 14
8 COSM6196604 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 14
9 COSM6191486 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 14

Expression for Thymus Cancer

Search GEO for disease gene expression data for Thymus Cancer.

Pathways for Thymus Cancer

GO Terms for Thymus Cancer

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cerebral cortex cell migration GO:0021795 8.96 EGFR NKX2-1
2 tongue development GO:0043586 8.62 EGFR KIT

Molecular functions related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 EGFR PIK3R2 TP53
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR KIT
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 EGFR KIT PIK3R2

Sources for Thymus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....